EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products

François Griaud iD, Patrick Sascha Merkle, Joachim Ritter, Victor Le-Minh, Haiyan Zhang, Maja Semanjski Curkovic, Stefan Mittermayr iD, Eva Kranjc iD, Nina Pirher, Jens Pettelkau, Markus Nienhaus-Stepath, Dominik Mertens und 10 weitere

Pharmaceuticals · 24.07.2026 · 19 (8) · 1147

DOI: 10.3390/ph19081147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 24.07.2026. Verfasst von François Griaud und 21 weiteren Autor:innen. Beteiligte Einrichtung: Technical Research & Development (TRD) Biologics Analytical Characterization, Novartis Pharma AG, 4002 Basel, Switzerland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Process characterization (PC) of biopharmaceutical products is intended to identify critical process parameters (CPPs) based on their impact on critical quality attributes (CQAs), as well as to define acceptable process parameter ranges to ensure consistent product quality and process performance. However, conventional analytical methods with indirect readouts, e.g., the sum of size/charge variants, often fall short in differentiating CQAs that have safety and efficacy relevance from product quality attributes (PQAs) that do not, thus limiting their utility in establishing a thorough process understanding. The Multi-Attribute Method (MAM) addresses these limitations by monitoring CQAs using the required resolution and specificity.

Methods

A MAM platform was developed, and its robust performance and reproducibility were demonstrated across six laboratories. The MAM platform was applied for the drug substance (DS) PC of two monoclonal antibodies and the analysis of up to a hundred PQAs across 472 and 644 samples, respectively. The MAM results were compared to data obtained with conventional methods like hydrophilic interaction chromatography–fluorescence detection (HILIC-FLD) and cation-exchange chromatography with UV detection (CEX-UV).

Results

The levels of PQAs, including succinimide, deamidation, glycosylation, and oxidation, were reproducible between six laboratories. Artefactual oxidation was limited by controlling the quality of TFA reagent. CPPs impacting the level of, e.g., oxidation, glycation, O-glycosylation, and N-glycan sialylation, were identified, leveraging a simultaneous, consistent, and fast MAM data analysis across all samples.

Conclusions

MAM enables high-resolution PC to identify CPPs and inform control strategies for CQAs that are not resolved by conventional methods.

Schlagwörter

Stichwörter der Autor:innen

MAMcritical process parametercritical quality attributedesign of experimentsmass spectrometrymulti-attribute methodprocess characterizationquality target product profile

Autor:innen und Institutionen

  • Technical Research & Development (TRD) Biologics Analytical Characterization, Novartis Pharma AG, 4002 Basel, Switzerland.
  • TRD Biologics Drug Substance Development, Novartis Pharma AG, 4002 Basel, Switzerland.
  • TRD Biologics Process Analytical Sciences, Novartis Pharmaceutical Manufacturing LLC, 1234 Mengeš, Slovenia.
  • TRD Biologics Analytical Characterization, Novartis Pharma, 6250 Kundl, Austria.
  • Genedata GmbH, 80339 Munich, Germany.
  • Genedata AG, 4051 Basel, Switzerland.

ORCID-Profile: François Griaud, Stefan Mittermayr, Eva Kranjc, Dariusz Janecki, Thomas Pohl

Förderung

  • Novartis Pharma AG

Zitieren

APA

Griaud, F., Merkle, P. S., Ritter, J., Le-Minh, V., Zhang, H., Semanjski Curkovic, M., Mittermayr, S., Kranjc, E., Pirher, N., Pettelkau, J., Nienhaus-Stepath, M., Mertens, D., Rey, G., Dayer, J., Lang, M., Hajduk, J., Jenny, C., Starck, M., Jamnik, T., …, & Pohl, T. (2026). Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products. Pharmaceuticals, 19(8), 1147. https://doi.org/10.3390/ph19081147

Vancouver

Griaud F, Merkle PS, Ritter J, Le-Minh V, Zhang H, Semanjski Curkovic M, et al. Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products. Pharmaceuticals. 2026;19(8):1147. doi:10.3390/ph19081147

BibTeX
@article{Griaud2026,
  author = {Griaud, François and Merkle, Patrick Sascha and Ritter, Joachim and Le-Minh, Victor and Zhang, Haiyan and Semanjski Curkovic, Maja and Mittermayr, Stefan and Kranjc, Eva and Pirher, Nina and Pettelkau, Jens and Nienhaus-Stepath, Markus and Mertens, Dominik and Rey, Guillaume and Dayer, Jérôme and Lang, Manuel and Hajduk, Joanna and Jenny, Camille and Starck, Michel and Jamnik, Thomas and Dotzauer, Lukas and Janecki, Dariusz and Pohl, Thomas},
  title = {Qualification and Implementation of a Robust Multi-Attribute Method Platform Across Multiple Laboratories for High-Resolution Process Characterization of Biopharmaceutical Products},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1147},
  doi = {10.3390/ph19081147}
}
Kostenlos starten →